The Level of Peptide YY in Blood Serum of Children With ChronicConstipation: A Cross-Sectional Study
https://doi.org/10.15690/vsp.v17i5.1955
Abstract
Background. The gastrointestinal polypeptide YY has an inhibitory effect on the colon motility, which can provoke constipation. The role of this peptide in the development of chronic constipation in children remains uninvestigated. Objective. Our aim was to determine the serum concentration of peptide YY in children with chronic constipation. Methods. A cross-sectional study included children aged 4–14 years with chronic constipation, who have been observed in the gastroenterology unit of the paediatric clinical hospital from March 2014 to September 2015. The control group was formed from healthy children. The diagnosis of chronic constipation was established based on the Rome criteria (2016). The blood serum level of peptide YY was determined by enzyme immunoassay after collecting serum samples from all study participants. Results. The study included 47 patients with chronic constipation (boys 62%; median age — 8 years) and 20 healthy children (boys 50%; median age — 7.5 years, compared with the main group p = 0.445). It has been found that children with chronic constipation had a lower blood serum concentration of peptide YY than healthy children: the median (25th; 75th percentile) was 0.68 (0.24; 1.43) and 2.34 (1.41; 3.35) ng/ml, respectively (p < 0.001). The level of peptide YY in the group of children with chronic constipation was not related to gender, age; the presence of colonoptosis, colonic/enteric reflux; the duration of chronic constipation, as well as to the occurrence of complications such as encopresis and colitis. Conclusion. Low blood serum levels of peptide YY were detected in children with chronic constipation.
About the Authors
Valentina N. PeregoedovaRussian Federation
Disclosure of interest: Not declared
Irina K. Bogomolova
Russian Federation
Disclosure of interest: Not declared
Mikhail P. Bryzgalin
Russian Federation
Disclosure of interest: Not declared
References
1. Zvyaginceva TD, Chernobai AI. Agonisty serotoninovykh retseptorov i sindrom razdrazhennogo kishechnika. Gazeta «Novosti meditsiny i farmatsii» Gastroenterologiya. 2010 may 8:(313). (In Russ).
2. Zaharova IN, Sugyan NG, Moskvich IK. Russian and international recommendations on management of constipations in children. Current pediatrics. 2014;13(1):74–83. (In Russ). doi: 10.15690/vsp.v13i1.914.
3. Belousova EA. Idiopathic slow-transit constipation: mechanisms of development and treatment potentials. Farmateka. 2010;(15):18–23. (In Russ).
4. Holzer P, Reichmann F, Farzi A. Neuropeptide Y, peptide YY and pancreatic polypeptide in the gut–brain axis. Neuropeptides. 2012;46(6):261–274. doi: 10.1016/j.npep.2012.08.005.
5. El-Salhy M, Mazzawi T, Gundersen D, et al. The role of peptide YY in gastrointestinal diseases and disorders (review). Int J Mol Med. 2013;31(2):275–282. doi: 10.3892/ijmm.2012.1222.
6. Tkachenko EV, Varvanina GG. Gormony pishchevogo povedeniya v patogeneze metabolicheskogo sindroma. Experimental and clinical gastroenterology. 2008;(5):56–59. (In Russ).
7. El-Salhy M, Norrgard O. Colonic neuroendocrine peptide levels in patients with chronic idiopathic slow transit constipation. Ups J Med Sci. 1998;103(3):223–230. doi: 10.3109/03009739809178951.
8. El-Salhy M, Gundersen D, Ostgaard H, et al. Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci. 2012;57(4):873–878. doi: 10.1007/s10620-011-1948-8.
9. Motoyama T, Katayama Y, Watanabe H, et al. Functioning ovarian carcinoids induce severe constipation. Cancer. 1992;70(2): 513–518. doi: 10.1002/1097-0142(19920715)70:2<513::aid-cncr2820700223>3.0.co;2-p.
10. Muller KE, Tafe LJ, Gonzalez JL, et al. Ovarian strumal carcinoid producing peptide YY associated with severe constipation: a case report and review of the literature. Int J Gynecol Pathol. 2015; 34(1):30–35. doi: 10.1097/PGP.0000000000000117.
11. Cooper JA. Factors affecting circulating levels of peptide YY in humans: a comprehensive review. Nutr Res Rev. 2014;27(1): 186–197. doi: 10.1017/S0954422414000109.
12. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130(5):1377–1390. doi: 10.1053/j.gastro.2006.03.008.
13. Tack J, Muller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation — a European perspective. Neurogastroenterol Motil. 2011;23(8):697–710. doi: 10.1111/j.1365-2982.2011.01709.x.
14. Saad RJ, Rao SS, Koch KL, et al. Do stool form and frequency correlate with whole-gut and colonic transit? Results from a multicenter study in constipated individuals and healthy controls. Am J Gastroenterol. 2010;105(2):403–411. doi: 10.1038/ajg.2009.612.
15. Yaegashi N, Tsuiki A, Shimizu T, et al. Ovarian carcinoid with severe constipation due to peptide YY production. Gynecol Oncol. 1995;56(2):302–306. doi: 10.1006/gyno.1995.1051.
16. Kawano K, Ushijima K, Fujimoto T, et al. Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. J Obstet Gynaecol Res. 2007;33(3):392–396. doi: 10.1111/j.1447-0756.2007.00544.x.
17. Konovalova-Kushnir TA. Mesto peptidnoi disregulyatsii v patogeneze sindroma razdrazhennogo kishechnika. Novosti meditsiny i farmatsii. 2013; (6):48–50. (In Russ).
18. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7(3):163–173. doi: 10.1038/nrgastro.2010.4.
19. Beck AL, Cabrera L, Pan WK, et al. Peptide YY: a gut hormone associated with anorexia during infectious diarrhea in children. J Pediatr. 2008;153(5):677–682. doi: 10.1016/j.jpeds.2008.04.065.
Review
For citations:
Peregoedova V.N., Bogomolova I.K., Bryzgalin M.P. The Level of Peptide YY in Blood Serum of Children With ChronicConstipation: A Cross-Sectional Study. Current Pediatrics. 2018;17(5):389-393. https://doi.org/10.15690/vsp.v17i5.1955